Improving the management of patients with preeclampsia using biomarkers: Everyone else is doing it, so why aren't we?

Tuesday, September 28, 11:30 a.m. - 12:30 p.m.
Exhibit Hall, Theater 1
Supported by Roche Diagnostics


Preeclampsia is a major cause of fetal and maternal morbidity and mortality, occurring in 2-8% of pregnancies worldwide.  Multiple studies have demonstrated an imbalance of angiogenic factors with preeclampsia, sometimes as early as 5 weeks prior to the onset of symptoms.  Outside of the United States, many countries have adopted biomarker analysis as part of the screening algorithm for preeclampsia. To date, testing is not yet clinically available in this country.  Liza Kunz, a practicing maternal fetal medicine specialist, will speak to the challenge of diagnosing preeclampsia and outline the impact of biomarker analysis worldwide


  • Understand the contribution of preeclampsia to US maternal morbidity and mortality.
  • Describe the current US standard of care for diagnosis and management of preeclampsia./li>
  • Describe how, outside the US, biomarkers are used as part of routine care.


Liza Kunz, MD, FACOG
Medical and Scientific Affairs
Roche Diagnostics